Nimotuzumab enhances radiation sensitivity of NSCLC H292 cells in vitro by blocking epidermal growth factor receptor nuclear translocation and inhibiting radiation-induced DNA damage repair

OncoTargets and Therapy

Volumn 8, Issue , 2015, Pages 809-818

  Teng, Kai ^a,b   Zhang, Yong ^a   Hu, Xiaoyan ^a   Ding, Yihui ^a   Gong, Rui ^a   Liu, Li ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Hainan Cancer Hospital   (China)

Author keywords

DNA PK; EGFR; Nimotuzumab; NSCLC; Nuclear translocation; Radiosensitivity

Indexed keywords

DNA DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA HISTONE H2AX; NIMOTUZUMAB; NUCLEAR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE DISTRIBUTION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PARAMETERS; CELL NUCLEUS; CELL SPECIFICITY; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; CYTOPLASM; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG CYTOTOXICITY; DRUG MECHANISM; ENZYME ACTIVATION; FLOW CYTOMETRY; H1975 CELL LINE; H292 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IONIZING RADIATION; LUNG CANCER CELL LINE; NON SMALL CELL LUNG CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT; RADIOSENSITIVITY; WESTERN BLOTTING;

EID: 84929396025     PISSN: 11786930     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S77283     Document Type: Article

References (32)

1. Jiang ZQ, Yang K, Komaki R, et al. Long-term clinical outcome of intensity-modulated radiotherapy for inoperable non-small cell lung cancer: the MD Anderson experience. Int J Radiat Oncol Biol Phys. 2012;83(1):332–339.
2. Liu HH, Wang X, Dong L, et al. Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004;58(4):1268–1279.
3. Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res. 2001;7(7):1850–1855.
4. Good JS, Harrington KJ. The hallmarks of cancer and the radiation oncologist: updating the 5Rs of radiobiology. Clin Oncol (R Coll Radiol). 2013;25(10):569–577.
5. Rivera F, Vega-Villegas ME, Lopez-Brea MF, Marquez R. Current situation of panitumumab, matuzumab, nimotuzumab and zalutumumab. Acta Oncol. 2008;47(1):9–19.
6. Crombet T, Torres L, Neninger E, et al. Pharmacological evaluation of humanized anti-epidermal growth factor receptor, monoclonal antibody h-R3, in patients with advanced epithelial-derived cancer. J Immunother. 2003;26(2):139–148.
7. Arfaoui A, Kriaa L, Znaidi N, et al. Over-expression of EGFR is closely correlated to poor prognosis in Tunisian patients with non-small cell lung adenocarcinoma. J Immunoassay Immunochem. 2014;35(3):256–268.
8. Jedlinski A, Ansell A, Johansson AC, Roberg K. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines. J Oral Pathol Med. 2013;42(1):26–36.
9. Akashi Y, Okamoto I, Iwasa T, et al. Enhancement of the antitumor activity of ionising radiation by nimotuzumab, a humanised monoclonal antibody to the epidermal growth factor receptor, in non-small cell lung cancer cell lines of differing epidermal growth factor receptor status. Br J Cancer. 2008;98(4):749–755.
10. Baumann M, Krause M, Dikomey E, et al. EGFR-targeted anti-cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol. 2007;83(3):238–248.
11. Dittmann K, Mayer C, Fehrenbacher B, et al. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem. 2005;280(35):31182–31189.
12. Delaney G, Jacob S, Featherstone C, Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer. 2005;104(6):1129–1137.
13. Crombet T, Osorio M, Cruz T, et al. Use of the humanized anti-epidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol. 2004;22(9):1646–1654.
14. Liang J, Mingyan E, Wu G, et al. Nimotuzumab combined with radiotherapy for esophageal cancer: preliminary study of a phase II clinical trial. Onco Targets Ther. 2013;6:1589–1596.
15. Diaz-Miqueli A, Martinez GS. Nimotuzumab as a radiosensitizing agent in the treatment of high grade glioma: challenges and opportunities. Onco Targets Ther. 2013;6:931–942.
16. Ramakrishnan MS, Eswaraiah A, Crombet T, et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin. MAbs. 2009;1(1):41–48.
17. Choi HJ, Sohn JH, Lee CG, et al. A phase I study of nimotuzumab in combination with radiotherapy in stages IIB-IV non-small cell lung cancer unsuitable for radical therapy: Korean results. Lung Cancer. 2011;71(1):55–59.
18. Bebb G, Smith C, Rorke S, et al. Phase I clinical trial of the anti-EGFR monoclonal antibody nimotuzumab with concurrent external thoracic radiotherapy in Canadian patients diagnosed with stage IIb, III or IV non-small cell lung cancer unsuitable for radical therapy. Cancer Chemother Pharmacol. 2011;67(4):837–845.
19. Garrido G, Tikhomirov IA, Rabasa A, et al. Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile. Cancer Biol Ther. 2011;11(4):373–382.
20. Iyer R, Thames HD, Tealer JR, Mason KA, Evans SC. Effect of reduced EGFR function on the radiosensitivity and proliferative capacity of mouse jejunal crypt clonogens. Radiother Oncol. 2004;72(3):283–289.
21. Qu YY, Hu SL, Xu XY, et al. Nimotuzumab enhances the radiosensitivity of cancer cells in vitro by inhibiting radiation-induced DNA damage repair. PLoS One. 2013;8(8):e70727.
22. Zhao L, Li QQ, Zhang R, et al. The overexpression of IGFBP-3 is involved in the chemosensitivity of esophageal squamous cell carcinoma cells to nimotuzumab combined with cisplatin. Tumour Biol. 2012;33(4):1115–1123.
23. Lum JJ, Bauer DE, Kong M, et al. Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell. 2005;120(2):237–248.
24. Li X, Fan Z. The epidermal growth factor receptor antibody cetuximab induces autophagy in cancer cells by downregulating HIF-1alpha and Bcl-2 and activating the beclin 1/hVps34 complex. Cancer Res. 2010;70(14):5942–5952.
25. Song H, Pan B, Yi J, Chen L. Featured article: autophagic activation with nimotuzumab enhanced chemosensitivity and radiosensitivity of esophageal squamous cell carcinoma. Exp Biol Med (Maywood). 2014;239(5):529–541.
26. Wang M, Morsbach F, Sander D, et al. EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks. Cancer Res. 2011;71(19):6261–6269.
27. Rothkamm K, Kuhne M, Jeggo PA, Lobrich M. Radiation-induced genomic rearrangements formed by nonhomologous end-joining of DNA double-strand breaks. Cancer Res. 2001;61(10):3886–3893.
28. Redon C, Pilch D, Rogakou E, Sedelnikova O, Newrock K, Bonner W. Histone H2A variants H2AX and H2AZ. Curr Opin Genet Dev. 2002;12(2):162–169.
29. Berger C, Krengel U, Stang E, Moreno E, Madshus IH. Nimotuzumab and cetuximab block ligand-independent EGF receptor signaling efficiently at different concentrations. J Immunother. 2011;34(7):550–555.
30. Talavera A, Friemann R, Gómez-Puerta S, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res. 2009;69(14):5851–5859.
31. Perez R, Moreno E, Garrido G, Crombet T. EGFR-targeting as a biological therapy: understanding nimotuzumab’s clinical. Cancers (Basel). 2011;3(2):2014–2031.
32. Takeda M, Okamoto I, Nishimura Y, Nakagawa K. Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer. Lung Cancer Targets Ther. 2011;2:59–67.